Sarah M. Schrader

Sarah M. Schrader

Auto-generated profile, based on publicly available information

Sarah M. Schrader

Department of Pathology, Massachusetts General Hospital

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
SSSarah M. Schrader
Sarah M. Schrader
JVJulien Vaubourgeix
Julien Vaubourgeix
CNCarl Nathan
Carl Nathan
Improved understanding of the resistance of bacterial pathogens to antibiotics is fueling fresh approaches to identify new compounds, bacterial targets, and drug regimens.

27 August 2021 in Science Advances
Verified
Journal Article
Open access
SSSarah M. Schrader
Sarah M. Schrader
HBHélène Botella
Hélène Botella
RJRobert Jansen
Robert Jansen
SESabine Ehrt
Sabine Ehrt
KRKyu Rhee
Kyu Rhee
JVJulien Vaubourgeix
Julien Vaubourgeix
Disruption of a metabolic pathway causes tolerance, high persistence, and MIC-shifted resistance to diverse antibiotics.

5 July 2024 in Clinical Chemistry
Verified
Journal Article
Closed access
PDF file
SSSarah M Schrader
Sarah M Schrader
Discrepancies between laboratory results obtained using different methods can be a source of confusion and frustration for patients and clinicians alike, especially when the results in question affect major treatment decisions. In this case, the authors describe discrepancies between protein quantities measured on an automated chemistry analyzer and via agarose gel serum protein electrophoresis (SPE) in a patient undergoing workup for suspected multiple myeloma. Through careful review of how the samples were stored and processed, they implicated cryoglobulins—immunoglobulins that reversibly precipitate at temperatures below 37°C—as the culprit. While the sample for the automated chemistry analyzer was processed immediately on receipt, the sample for SPE was stored refrigerated overnight before processing, allowing the cryoglobulins to precipitate out of solution and affecting the SPE results. This case shows how a thorough review of preanalytic and analytic factors by the clinical laboratory can help to explain discrepancies, offering clinicians confidence in the accuracy of the results they use to make crucial patient care decisions.

6 May 2026 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
SSSarah M. Schrader
Sarah M. Schrader
ZPZachary Pearson
Zachary Pearson
STSamantha Taffner
Samantha Taffner
SKSanjat Kanjilal
Sanjat Kanjilal
NPNicole Pecora
Nicole Pecora
Cefepime is generally recommended for treatment of clinically significant AmpC producers, including Citrobacter freundii complex ( Cfre ), Enterobacter cloacae complex ( Eclo ), and Klebsiella aerogenes ( Kaer ). Clinicians increasingly use the results of multiplex PCR panels to make early treatment decisions, with cefepime often chosen when an AmpC producer is detected without a bla CTX-M extended-spectrum beta-lactamase (ESBL) or carbapenemase. To understand the safety of this approach, we evaluated the prevalence of cefepime resistance among 4,687 Cfre ; 9,878 Eclo ; and 4,800 Kaer clinical isolates collected in our hospital network in New England, USA, from 2015 to 2024. We additionally reviewed Blood Culture Identification 2 (BCID2) (bioMérieux) results for 136 blood cultures and the sequenced genomes of 184 isolates (14 cefepime-susceptible dose-dependent [SDD], 34 cefepime-resistant). Cefepime-SDD and cefepime-resistant isolates made up 0.4% (18/4,687) and 1.3% (59/4,687) of Cfre , 2.0% (194/9,879) and 3.0% (299/9,879) of Eclo , and 0.3% (16/4,800) and 0.6% (28/4,800) of Kaer . Of 117 Eclo and Kaer identified in blood cultures on the BCID2, 4.3% (5/117) were cefepime-SDD or cefepime-resistant and negative for an ESBL or carbapenemase target. Among sequenced cefepime-SDD isolates, 21% (3/14) carried an ESBL. Cefepime-resistant isolates carried diverse beta-lactamase genes, including ESBL genes, carbapenemase genes, and plasmid-borne ampC . While reduced cefepime susceptibility was generally associated with carriage of more beta-lactamase genes, 57% of cefepime-SDD and 35% of cefepime-resistant isolates encoded only chromosomal ampC . Our results highlight variable cefepime susceptibility rates for AmpC producers across clinical settings and demonstrate diverse mechanisms underlying reduced cefepime susceptibility.

8 July 2026 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
SSSarah M. Schrader
Sarah M. Schrader
VTVamsi Thiriveedhi
Vamsi Thiriveedhi
JBJohn A. Branda
John A. Branda
STSarah E. Turbett
Sarah E. Turbett
EKErik H. Klontz
Erik H. Klontz
Fungal and mycobacterial smear and culture are often inappropriately ordered, straining clinical laboratory resources and risking patient harm from false-positive results. To identify opportunities for optimization, we assessed utilization and yield of fungal and mycobacterial smear and culture over five years at a large academic medical center in an area of low tuberculosis prevalence. Positive rates were generally lower for non-respiratory specimens compared to respiratory specimens, prompting us to focus on collection method (swab vs non-swab) and location (operating room [OR] vs non-OR) for non-respiratory specimens. For non-respiratory fungal smear and culture, swabs demonstrated poor recovery of mold in culture, and positive smear results from swabs rarely affected clinical management (6/3,611 cases [0.17%]). Positive rates were significantly lower among OR specimens. For mycobacterial smear and culture, positive rates were exceedingly low for non-respiratory specimens (smear: 70/23,661 [0.3%]; culture: 278/23,918 [1.2%]). Swabs were inferior for mycobacterial culture, and positive smear results from swabs rarely impacted clinical management (3/7,398 cases [0.04%]). Among patients with at least one non-respiratory mycobacterial smear or culture over a two-year period, the smear or culture was diagnostic in only 32/4,572 (0.70%), 31 (96.9%) of whom had risk factors for mycobacterial infection. The smear result changed clinical management in only 5/4,497 cases (0.11%). Our results reveal considerable overutilization of fungal and mycobacterial smear and culture for non-respiratory specimens and confirm the low yield of non-respiratory swabs for mold and mycobacterial detection. These data inform strategies to optimize fungal and mycobacterial diagnostic testing in clinical laboratories. IMPORTANCE: Fungal and mycobacterial infections are associated with specific risk factors. However, diagnostic studies for fungal and mycobacterial infections, including fungal and mycobacterial smear and culture, are often inappropriately ordered in clinical scenarios where the probability of infection is low. Due to the manual nature of these tests, high volumes of unnecessary testing strain limited clinical laboratory resources. In addition, patients can be harmed by false-positive results. In this study, we analyzed the results of fungal and mycobacterial smear and culture performed over five years at a large academic medical center in a location with low tuberculosis prevalence to identify strategies to reduce unnecessary testing. Implementation of these strategies could allow clinical laboratories to optimize fungal and mycobacterial diagnostic testing and more efficiently use limited clinical laboratory resources without compromising patient care.